Cargando…
Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System
INTRODUCTION: Tight glycemic control and timely treatment can improve outcomes in patients with diabetes yet many remain sub-optimally controlled. The objective of the current study was to evaluate the effect of switching patients with sub-optimally controlled diabetes to the V-Go(®) (Valeritas Inc....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674471/ https://www.ncbi.nlm.nih.gov/pubmed/26470692 http://dx.doi.org/10.1007/s13300-015-0138-7 |
_version_ | 1782404899414212608 |
---|---|
author | Lajara, Rosemarie Fetchick, Dianne A. Morris, Tracy L. Nikkel, Carla |
author_facet | Lajara, Rosemarie Fetchick, Dianne A. Morris, Tracy L. Nikkel, Carla |
author_sort | Lajara, Rosemarie |
collection | PubMed |
description | INTRODUCTION: Tight glycemic control and timely treatment can improve outcomes in patients with diabetes yet many remain sub-optimally controlled. The objective of the current study was to evaluate the effect of switching patients with sub-optimally controlled diabetes to the V-Go(®) (Valeritas Inc., Bridgewater, NJ, USA) Disposable Insulin Delivery device. METHODS: A retrospective analysis of electronic medical records was conducted to assess patients with sub-optimal glycemic control defined as a glycated hemoglobin (HbA1c) >7%, switched to V-Go. Blood glucose control defined as change from baseline in HbA1c, prescribed insulin doses, body weight, concomitant anti-hyperglycemic agents, and reported hypoglycemia were collected prior to switching to V-Go and during V-Go use. RESULTS: Two-hundred and four patients were evaluated during the study period. Overall, there was a significant decrease in HbA1c after switching to V-Go at the 14- and 27-week follow-up visits. The least-squares mean (LSM) change in HbA1c (95% confidence interval) from baseline to 14 weeks was −1.53% (−1.69% to −1.37%; P < 0.001), and from baseline to 27 weeks was −1.79% (−1.97% to −1.61%; P < 0.001). Significant reductions in mean HbA1c were achieved at both visits in all patient subsets: Patients with type 2 and type 1/latent autoimmune diabetes in adults (LADA); patients using insulin at baseline and patients naïve to insulin at baseline. Patients administering insulin at baseline required significantly less insulin on V-Go (86–99 LSM units/day at baseline to 58 LSM units/day at 27 weeks; P < 0.001). Across all patients, reported hypoglycemic events were no more frequent on V-Go than on previous therapy. CONCLUSION: V-Go is safe and effective in patients with sub-optimally controlled diabetes requiring insulin therapy. Glycemic control improved significantly, less insulin was required, and hypoglycemic events were similar after patients switched to insulin delivery by V-Go. FUNDING: Valeritas, Inc. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-015-0138-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4674471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-46744712015-12-17 Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System Lajara, Rosemarie Fetchick, Dianne A. Morris, Tracy L. Nikkel, Carla Diabetes Ther Original Research INTRODUCTION: Tight glycemic control and timely treatment can improve outcomes in patients with diabetes yet many remain sub-optimally controlled. The objective of the current study was to evaluate the effect of switching patients with sub-optimally controlled diabetes to the V-Go(®) (Valeritas Inc., Bridgewater, NJ, USA) Disposable Insulin Delivery device. METHODS: A retrospective analysis of electronic medical records was conducted to assess patients with sub-optimal glycemic control defined as a glycated hemoglobin (HbA1c) >7%, switched to V-Go. Blood glucose control defined as change from baseline in HbA1c, prescribed insulin doses, body weight, concomitant anti-hyperglycemic agents, and reported hypoglycemia were collected prior to switching to V-Go and during V-Go use. RESULTS: Two-hundred and four patients were evaluated during the study period. Overall, there was a significant decrease in HbA1c after switching to V-Go at the 14- and 27-week follow-up visits. The least-squares mean (LSM) change in HbA1c (95% confidence interval) from baseline to 14 weeks was −1.53% (−1.69% to −1.37%; P < 0.001), and from baseline to 27 weeks was −1.79% (−1.97% to −1.61%; P < 0.001). Significant reductions in mean HbA1c were achieved at both visits in all patient subsets: Patients with type 2 and type 1/latent autoimmune diabetes in adults (LADA); patients using insulin at baseline and patients naïve to insulin at baseline. Patients administering insulin at baseline required significantly less insulin on V-Go (86–99 LSM units/day at baseline to 58 LSM units/day at 27 weeks; P < 0.001). Across all patients, reported hypoglycemic events were no more frequent on V-Go than on previous therapy. CONCLUSION: V-Go is safe and effective in patients with sub-optimally controlled diabetes requiring insulin therapy. Glycemic control improved significantly, less insulin was required, and hypoglycemic events were similar after patients switched to insulin delivery by V-Go. FUNDING: Valeritas, Inc. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-015-0138-7) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-10-15 2015-12 /pmc/articles/PMC4674471/ /pubmed/26470692 http://dx.doi.org/10.1007/s13300-015-0138-7 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Lajara, Rosemarie Fetchick, Dianne A. Morris, Tracy L. Nikkel, Carla Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System |
title | Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System |
title_full | Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System |
title_fullStr | Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System |
title_full_unstemmed | Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System |
title_short | Use of V-Go(®) Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System |
title_sort | use of v-go(®) insulin delivery device in patients with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674471/ https://www.ncbi.nlm.nih.gov/pubmed/26470692 http://dx.doi.org/10.1007/s13300-015-0138-7 |
work_keys_str_mv | AT lajararosemarie useofvgoinsulindeliverydeviceinpatientswithsuboptimallycontrolleddiabetesmellitusaretrospectiveanalysisfromalargespecializeddiabetessystem AT fetchickdiannea useofvgoinsulindeliverydeviceinpatientswithsuboptimallycontrolleddiabetesmellitusaretrospectiveanalysisfromalargespecializeddiabetessystem AT morristracyl useofvgoinsulindeliverydeviceinpatientswithsuboptimallycontrolleddiabetesmellitusaretrospectiveanalysisfromalargespecializeddiabetessystem AT nikkelcarla useofvgoinsulindeliverydeviceinpatientswithsuboptimallycontrolleddiabetesmellitusaretrospectiveanalysisfromalargespecializeddiabetessystem |